Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Sarah McCuaig¹, Julia Rood¹, Em Elliott¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²CHOP, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1817 • ACR Convergence 2025
Sex-specific mechanisms associated with female childhood-onset systemic lupus erythematosus revealed by transcriptomic analysis of transgender adolescents undergoing gender-affirming sex hormone therapy.
Heather Cross¹, Hannah Peckham¹, Gary Butler², Elizabeth Rosser³, Elizabeth C Jury¹, George Robinson¹ and Coziana Ciurtin¹, ¹University College London, London, United Kingdom, ²University College London Hospital NHS Trust, London, England, United Kingdom, ³University College London, London, England, United Kingdom
Background/Purpose: Sex determinants may play a role in the immunological sexual dimorphism of childhood-onset systemic lupus erythematosus (cSLE). This study aimed to investigate the impact…
Abstract Number: 1717 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Anubhav Singh⁴, Cristina Reategui-Sokolova⁵, Claudia Elera-Fitzcarrald⁵, Samira Garcia-Hirsh⁶, Cesar Pastor-Asurza⁷, Zoila Rodriguez-Bellido⁸, Risto Perich-Campos⁹, Graciela Alarcón¹⁰ and Manuel Ugarte-Gil¹¹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Baptist hospital of southeast Texas, Beaumont, TX, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁸Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁹Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ¹⁰The University of Alabama at Birmingham, Oakland, CA, ¹¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Frailty has been shown to predict damage accrual in patients with SLE, including those from Latin America. However, the impact of frailty on mortality…
Abstract Number: 1634 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus With Incident Heart Failure Requiring Hospitalization
Chun-Yu Lin, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan (Republic of China)
Background/Purpose: Cardiovascular complications are increasingly recognized as a significant cause of late mortality in patients with systemic lupus erythematosus (SLE). Although coronary heart disease risk…
Abstract Number: 1538 • ACR Convergence 2025
Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Minoru Hasegawa¹, Jun Kinoshita², Shigeki Otsubo³, Kana Yamada³ and Ehsanollah Esfandiari⁴, ¹Division of Medicine, University of Fukui, Yoshida-gun, Fukui, Japan, ²Kyowa Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Kyowa Kirin Co., Ltd., Tokyo, Japan, ⁴Kyowa kirin International plc, London, United Kingdom
Background/Purpose: Plasmacytoid dendritic cells (pDCs) are known to be the main source of type 1 interferon (IFN), which is the cause of various autoimmune diseases.…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1496 • ACR Convergence 2025
Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Manikandan Gopal¹, Ashish Jacob Mathew² and john mathew³, ¹christian medical college, Vellore, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) with acute myelitis or optic neuritis is rare and causes significant morbidity. Data on these conditions remain limited. This study…
Abstract Number: 1479 • ACR Convergence 2025
Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Chen Chao¹, Garrett Thomas², Catherine O’Brien², Davina Chen³, Sundus Mian⁴, Tamar Rubinstein⁵, Noa Schwartz⁴ and Bryan Freilich², ¹Rheumatology Division, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, NY, ²Department of Psychiatry, Montefiore Medical Center, Bronx, NY, ³Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New Rochelle, NY, ⁴Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ⁵Albert Einstein College of Medicine, White Plains, NY
Background/Purpose: Up to 80% of Systemic Lupus Erythematosus (SLE) patients experience cognitive dysfunction (CD), which is a top distressing symptom affecting their quality of life.(1)…
Abstract Number: 1296 • ACR Convergence 2025
Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
Meredith Rae¹, Dawn Gist², Kaylani Patel³, Krupa Mysore³, Andrea Ramirez², Marietta De Guzman² and Eyal Muscal², ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston
Background/Purpose: Distinguishing lupus hepatitis (LH) from autoimmune hepatitis (AIH) in SLE is clinically challenging but critical for guiding treatment duration. The mechanisms differ; AIH results…
Abstract Number: 1240 • ACR Convergence 2025
Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Sarah Keegan¹, Philip Carlucci², Peter Izmirly³, Erin Carter⁴, Sanchit Sanyal⁵, Brooke Cohen⁶, Jasmine Shwetar⁷, Katie Preisinger⁸, Devyn Zaminski⁶, Kristina Deonaraine⁶, Mala Masson⁹, Andrea Fava¹⁰, Judith James¹¹, Rufei Lu¹¹, Wade DeJager¹², Chaim Putterman¹³, Michael Belmont¹⁴, Richard Furie¹⁵, Maria Dall'Era¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, Jennifer Anolik¹⁹, David Wofsy²⁰, Jennifer Barnas²¹, Nir Hacohen²², Robert Clancy²³, Joel Guthridge¹¹, Brad Rovin²⁴, Michelle Petri²⁵, Jill Buyon³ and Kelly Ruggles²⁶, ¹NYU Langone, New York, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶NYU Langone, NYC, ⁷New York University School of Medicine, Department of Medicine, New York, ⁸NYU Langone, NYU Langone, ⁹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Albert Einstein College of Medicine, Safed, Israel, ¹⁴NYU Langone Health, New York, NY, ¹⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰University of California San Francisco, SF, CA, ²¹University of Rochester, Rochester, NY, ²²Broad Institute of MIT Harvard, Cambridge, MA, ²³Columbia University, New York, NY, ²⁴The Ohio State University, Columbus, OH, ²⁵Johns Hopkins University School of Medicine, Timonium, MD, ²⁶NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: For patients with lupus nephritis, active disease can be solely renal or include a range of extrarenal signs, such as arthritis or serositis, that…
Abstract Number: 1051 • ACR Convergence 2025
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Isabella Hartel¹, David Gazeley², Jay Patel¹, Betty Chewning³, Shelby Gomez⁴, Jessica Michaud⁵, Laura Dickmann⁶, Jon keevil⁷, Patricia Tellez-giron¹, Christie Bartels⁸ and Shivani Garg⁹, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, Madison, WI, ⁶Medical College of Wisconsin, Milwaukee, Milwaukee, ⁷N/A, Madison, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival in lupus (SLE). Yet, ~80% of patients stop taking HCQ resulting in poor outcomes including early mortality.…
Abstract Number: 0939 • ACR Convergence 2025
Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
Chengfeng Xue¹, Jingjing Wang¹, Mengwen Huang¹, Ting Liu¹, Panpan Wang¹, Donghai Chen², Xue Wang¹, Yawei Xu¹, Yajun Gong¹, Jun Yang¹, Xiaoshan Yu¹, Ke Wang¹, Yuqing Zhu¹, Kaixuan Zhu¹, Tianqi Tang¹, Wantong Qi¹, Yaqiong Pei¹, Qiyao Zhang¹, Fugang Li², Qingyang Gu¹ and Xiangnan Qiang¹, ¹WuXi AppTec, Shanghai, China (People's Republic), ²WuXi ApptTec, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and immunological manifestations. Bruton’s tyrosine kinase (BTK) is a crucial intracellular kinase in…
Abstract Number: 0707 • ACR Convergence 2025
When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?
Samiha Karim¹, Gaobin Bao¹, Charmayne Dunlop-Thomas¹ and S. Sam Lim², ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: People from underrepresented groups with SLE can face barriers to health care and management, including discrimination and a lack of resources and social and…
Abstract Number: 0645 • ACR Convergence 2025
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Eric Morand¹, Lucy Carter², Maria Dall'Era³, Michelle Petri⁴, Ed Vital⁵, Teri Jimenez⁶, Janine Gaiha-Rohrbach⁷, Bernard Lauwerys⁸, Annette Nelde⁹, Christian Stach¹⁰ and Ronald van Vollenhoven¹¹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Division of Rheumatology, University of California, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵University of Leeds, Leeds, England, United Kingdom, ⁶UCB, Raleigh, NC, ⁷Biogen, Cambridge, MA, ⁸Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ⁹Biogen, Baar, Switzerland, ¹⁰UCB, Monheim am Rhein, Germany, ¹¹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects on SLE immunopathology;1,2 it consists of a polyethylene glycol (PEG)-conjugated antigen-binding fragment…
Abstract Number: 0627 • ACR Convergence 2025
Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Omer Pamuk¹ and Ahmed Nasuhbeyoglu², ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Previous studies have shown a decline in systemic lupus erythematosus (SLE)-related mortality rates from 1999 to 2020. This study aimed to evaluate SLE-related mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].